Thu. 11 Apr 2024, 7:06am ET
Benzinga
Biotech, M&A, News, Health Care, Financing, General
- Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile
- Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026
- Acquisition of Clade Therapeutics strengthens Century's position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform
- Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade's αβ iT platform spanning across cancer and autoimmune diseases